A detailed history of Martingale Asset Management L P transactions in Vaxcyte, Inc. stock. As of the latest transaction made, Martingale Asset Management L P holds 15,605 shares of PCVX stock, worth $1.43 Million. This represents 0.04% of its overall portfolio holdings.

Number of Shares
15,605
Previous 17,269 9.64%
Holding current value
$1.43 Million
Previous $1.3 Million 36.68%
% of portfolio
0.04%
Previous 0.03%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$70.52 - $117.12 $117,345 - $194,887
-1,664 Reduced 9.64%
15,605 $1.78 Million
Q2 2024

Aug 12, 2024

BUY
$60.06 - $78.77 $85,825 - $112,562
1,429 Added 9.02%
17,269 $1.3 Million
Q1 2024

May 14, 2024

SELL
$59.79 - $81.05 $179 - $243
-3 Reduced 0.02%
15,840 $1.08 Million
Q4 2023

Feb 12, 2024

BUY
$45.35 - $63.41 $718,480 - $1 Million
15,843 New
15,843 $994,000
Q3 2022

Nov 14, 2022

BUY
$21.69 - $28.53 $726,896 - $956,125
33,513 New
33,513 $806,000

Others Institutions Holding PCVX

About Vaxcyte, Inc.


  • Ticker PCVX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,315,100
  • Market Cap $5.42B
  • Description
  • Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company a...
More about PCVX
Track This Portfolio

Track Martingale Asset Management L P Portfolio

Follow Martingale Asset Management L P and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Martingale Asset Management L P, based on Form 13F filings with the SEC.

News

Stay updated on Martingale Asset Management L P with notifications on news.